Advertisement

The Italian Journal of Neurological Sciences

, Volume 5, Issue 3, pp 285–287 | Cite as

Failure of carbamazepine to prevent clonazepam withdrawal status epilepticus

  • Sechi G. P. 
  • Zoroddu G. 
  • Rosati G. 
Original Articles

Abstract

We describe two patients in whom clonazepam withdrawal status epilepticus occurred in spite of therapeutic levels of carbamazepine in plasma and cere-brospinal fluid. The failure of carbamazepine to prevent clonazepam withdrawal status epilepticus is discussed.

Key-words

Carbamazepine Clonazepam withdrawal status epilepticus 

Sommario

Gli autori riportano due casi di stato di male epilettico da sospensione di clonazepam nonostante i livelli terapeutici di carbamazina nel plasma e nel liquor. La mancanza di efficacia della carbamazepina nel prevenire lo stato di male epilettico da sospensione di clonazepam viene discussa.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Bastie Y.:Depakine in the prevention of epileptic attacks during alcohol withdrawal. Ann Med Psychol 128: 400–404, 1970.Google Scholar
  2. [2]
    Bjorquist SE, Isohanni M., Makela R. et al.:Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: A formal multicentre double-blind comparison with placebo. Acta Psychiatric Scand 53: 333–342, 1976.Google Scholar
  3. [3]
    Cavazzutti G.B.:Prevention of febrile convulsions with dipropylacetate (Depakine). Epilepsia 16: 647–648, 1975.PubMedGoogle Scholar
  4. [4]
    Chu N-S.:Carbamazepine: Prevention of alcohol withdrawal seizures. Neurology 29: 1397–1401, 1979.PubMedGoogle Scholar
  5. [5]
    Edwards V.E.:Side effects of clonazepam therapy Proc Aust Assoc Neurol ii: 199–202, 1974.Google Scholar
  6. [6]
    Hillbom M.E.:The prevention of ethanol withdrawal seizures in rats by dipropylacetate. Neuropharmacology 14: 755–761, 1975.PubMedGoogle Scholar
  7. [7]
    Johannessen SI, Gerna M., Bakke J. et al.:CSF concentrations and serum protein binding of carbamazepine and carbamazepine 10, 11-epoxide in epileptic patients. Br J Clin Pharmacol 3: 575–582, 1976.Google Scholar
  8. [8]
    Knop H.J., Van Der Kleijn E., andEdmunds L.C.:Pharmacokinetics of clonazepam in man and laboratory animals. In: Schneider H., Janz D., Gardner-Thorpe C., Meinardi H., Sherwin A.L. (Eds), Clinical Pharmacology of Antiepileptic Drugs, Springer-Verlag, Berlin-Heidelberg, pp 247–260, 1975.Google Scholar
  9. [9]
    Lockard J.S., Levy R.H., Congdon W.C. et al.:Clonazepam in focal-motor monkey model: Efficacy, tolerance, toxicity, withdrawal and management. Epilepsia 20: 683–695, 1979.PubMedGoogle Scholar
  10. [10]
    Monaco F., Sechi G.P., Mutani R. et al.:Lack of efficacy of carbamazepine in preventing the recurrence of febrile convulsions.In: Johannessen S.I., Morselli P.L., Pippenger C.E., Richens A., Schmidt D. and Meinardi H. (Eds), Antiepileptic Therapy: Advances in Drug Monitoring, Raven Press, New York, pp 75–79, 1980.Google Scholar

Copyright information

© Masson Italia Periodici S.r.l. 1984

Authors and Affiliations

  • Sechi G. P. 
    • 1
  • Zoroddu G. 
    • 1
  • Rosati G. 
    • 1
  1. 1.Clinica NeurologicaUniversità di SassariItalia

Personalised recommendations